Literature DB >> 3878366

O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells.

S L Gerson, K Miller, N A Berger.   

Abstract

The association between alkylating agent exposure and acute nonlymphocytic leukemia in humans indicates that myeloid cells may be particularly susceptible to mutagenic damage. Alkylating agent mutagenesis is frequently mediated through formation and persistence of a particular DNA base adduct, O6alkylguanine, which preferentially mispairs with thymine rather than cytosine, leading to point mutations. O6alkylguanine is repaired by O6alkylguanine-DNA alkyltransferase (alkyltransferase), a protein that removes the adduct, leaving an intact guanine base in DNA. We measured alkyltransferase activity in myeloid precursors and compared it with levels in other cells and tissues. In peripheral blood granulocytes, monocytes, T lymphocytes, and B lymphocytes, there was an eightfold range of activity between individuals but only a twofold range in the mean activity between cell types. Normal donors maintained stable levels of alkyltransferase activity over time. In bone marrow T lymphocytes and myeloid precursors, there was an eightfold range of alkyltransferase activity between donors. Alkyltransferase activity in the two cell types was closely correlated in individual donors, r = 0.69, P less than 0.005, but was significantly higher in the T lymphocytes than the myeloid precursors, P less than 0.05. Liver contained the highest levels of alkyltransferase of all tissues tested. By comparison, small intestine contained 34%, colon 14%, T lymphocytes 11%, brain 11%, and myeloid precursors 6.6% of the activity found in liver. Thus, human myeloid precursors have low levels of O6alkylguanine-DNA alkyltransferase compared with other tissues. Low levels of this DNA repair protein may increase the susceptibility of myeloid precursors to malignant transformation after exposure to certain alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3878366      PMCID: PMC424319          DOI: 10.1172/JCI112215

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Methylation of DNA in various organs of C57B1 mice by a carcinogenic dose of N-methyl-N-nitrosourea and stabiltty of some methylation products up to 18 hours.

Authors:  J V Frei; P D Lawley
Journal:  Chem Biol Interact       Date:  1975-06       Impact factor: 5.192

2.  Interindividual variation in the activity of O6-methyl guanine-DNA methyltransferase and uracil-DNA glycosylase in human organs.

Authors:  B Myrnes; K E Giercksky; H Krokan
Journal:  Carcinogenesis       Date:  1983-12       Impact factor: 4.944

3.  Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations.

Authors:  S Sukumar; V Notario; D Martin-Zanca; M Barbacid
Journal:  Nature       Date:  1983 Dec 15-21       Impact factor: 49.962

4.  Amplification of pyridine nucleotide pools in mitogen-stimulated human lymphocytes.

Authors:  N A Berger; S J Berger; G W Sikorski; D M Catino
Journal:  Exp Cell Res       Date:  1982-01       Impact factor: 3.905

5.  Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas.

Authors:  D A Scudiero; S A Meyer; B E Clatterbuck; M R Mattern; C H Ziolkowski; R S Day
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

6.  Abilities of extracts of human lymphocytes to remove O6-methylguanine from DNA.

Authors:  E A Waldstein; E H Cao; M A Bender; R B Setlow
Journal:  Mutat Res       Date:  1982-08       Impact factor: 2.433

7.  O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors.

Authors:  O Wiestler; P Kleihues; A E Pegg
Journal:  Carcinogenesis       Date:  1984-01       Impact factor: 4.944

8.  O6-Methylguanine-DNA transmethylase activity in extracts of human gastric mucosa.

Authors:  S A Kyrtopoulos; B Vrotsou; B Golematis; M Bonatsos; G Lakiotis
Journal:  Carcinogenesis       Date:  1984-07       Impact factor: 4.944

9.  Release of granulocyte-specific colony-stimulating activity by human bone marrow exposed to phorbol esters.

Authors:  S L Gerson; R A Cooper
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

10.  Myelopoiesis following phorbol ester exposure in human long-term bone marrow cell culture.

Authors:  S L Gerson; R A Cooper
Journal:  Leuk Res       Date:  1984       Impact factor: 3.156

View more
  29 in total

1.  Proliferation is necessary for both repair and mutation in transgenic mouse cells.

Authors:  J H Bielas; J A Heddle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 2.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

3.  Direct assay for O6-methylguanine-DNA methyltransferase and comparison of detection methods for the methylated enzyme in polyacrylamide gels and electroblots.

Authors:  G N Major; E J Gardner; P D Lawley
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

4.  The Saccharomyces cerevisiae MGT1 DNA repair methyltransferase gene: its promoter and entire coding sequence, regulation and in vivo biological functions.

Authors:  W Xiao; L Samson
Journal:  Nucleic Acids Res       Date:  1992-07-25       Impact factor: 16.971

5.  In vitro erythropoiesis from bone marrow-derived progenitors provides a physiological assay for toxic and mutagenic compounds.

Authors:  J Shuga; J Zhang; L D Samson; H F Lodish; L G Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

6.  Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.

Authors:  Michael D Milsom; Moran Jerabek-Willemsen; Chad E Harris; Axel Schambach; Emily Broun; Jeff Bailey; Michael Jansen; David Schleimer; Kalpana Nattamai; Jamie Wilhelm; Amanda Watson; Hartmut Geiger; Geoffrey P Margison; Thomas Moritz; Christopher Baum; Jürgen Thomale; David A Williams
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.

Authors:  Jennifer E Adair; Brian C Beard; Grant D Trobridge; Tobias Neff; Jason K Rockhill; Daniel L Silbergeld; Maciej M Mrugala; Hans-Peter Kiem
Journal:  Sci Transl Med       Date:  2012-05-09       Impact factor: 17.956

Review 8.  Chemoprotection of normal tissues by transfer of drug resistance genes.

Authors:  J A Rafferty; I Hickson; N Chinnasamy; L S Lashford; G P Margison; T M Dexter; L J Fairbairn
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 9.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

10.  O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.

Authors:  A J Watson; M R Middleton; G McGown; M Thorncroft; M Ranson; P Hersey; G McArthur; I D Davis; D Thomson; J Beith; A Haydon; R Kefford; P Lorigan; P Mortimer; A Sabharwal; O Hayward; G P Margison
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.